natgillin/translations-raw huggingface dataset:
Der var en mindre stigning i plasmakoncentrationerne af capecitabin og en af metabolitterne (5’DFCR), men ingen virkning på de 3 hovedmetabolitter (5’DFUR, 5-FU og FBAL).
There was a small increase in plasma concentrations of capecitabine and one metabolite (5’-DFCR); there was no effect on the 3 major metabolites (5’-DFUR, 5-FU and FBAL).
Der var en numerisk forskel i ikke-kardiovaskulær død med flere hændelser på saxagliptin (1,8 %) end på placebo (1,4 %) [HR=1,27; (95 % CI 1,00, 1,62); P=0,051].
There was a numerical imbalance in non-CV death, with more events on saxagliptin (1.8%) than placebo (1.4%) [HR=1.27; (95% CI 1.00, 1.62); P=0.051].
Der var en rapport om CTCAE grad 3 post- herpetisk neuralgi blandt PV-patienter.
There was one report of CTCAE grade 3 post-herpetic neuralgia amongst the PV patients.
Der var en sammenhæng mellem niveauerne af shed-antigen og serum-aspartat- aminotransferase; en del af shed-antigenets indvirkning på clearance kan muligvis forklares ud fra serum-aspartat-aminotransferase niveauet.
There was a correlation between shed antigen and SGOT/AST levels; part of the impact of shed antigen on clearance may have been explained by SGOT/AST levels.
Der var en signifikant højere tumor respons på 14,4 % (95 %CI: 9,6-19,3) hos patienter i JEVTANA armen sammenlignet med 4,4 % (95 %CI: 1,6-7,2) hos patienter i mitoxantron armen, p=0,0005.
There was a significant higher rate of tumour response of 14.4% (95%CI: 9.6-19.3) in patients in the JEVTANA arm compared to 4.4% (95%CI: 1.6-7.2) for patients in the mitoxantrone arm, p=0.0005.
Der var en signifikant større andel af patienter i tocilizumab 8 mg/kg + MTX og tocilizumab-monoterapi-grupperne, som nåede det primære endepunkt, sammenlignet med MTX-monoterapi-gruppen.
A significantly higher proportion of patients in the tocilizumab 8 mg/kg + MTX and tocilizumab monotherapy groups met the primary endpoint compared with MTX alone.
Der var en signifikant terapeutisk fordel ved brug af enoxaparin i sammenlignet med UFH hos patienter, der fik foretaget perkutan koronar angioplastik inden for 30 dage efter randomisering (reduktion på 23 % af den relative risiko) eller konservativ behandling (reduktion på 15 % af den relative risiko, p = 0,27 for interaktion).
There was a significant therapeutic benefit from the use of enoxaparin in comparison to UFH in patients undergoing percutaneous coronary angioplasty within 30 days after the random sampling (relative risk reduction of 23%) or conservative treatment (reduction of relative risk of 15%, p = 0.27 for interaction).
Der var en signifikant terapeutisk fordel ved brug af enoxaparin i sammenligning med UFH hos patienter, der fik foretaget perkutan koronar angioplastik inden for 30 dage efter den vilkårlige prøvetagning (reduktion på 23 % af den relative risiko) eller konservativ behandling (reduktion på 15 % af den relative risiko, p = 0,27 for interaktion).
There was a significant therapeutic benefit from the use of enoxaparin in comparison to UFH in patients undergoing percutaneous coronary angioplasty within 30 days after the random sampling (relative risk reduction of 23%) or conservative treatment (reduction of relative risk of 15%, p = 0.27 for interaction).
Der var en signifikant terapeutisk fordel ved brug af enoxaparin sammenlignet med UFH hos patienter, der fik foretaget perkutan koronar angioplastik inden for 30 dage efter randomisering (reduktion på 23 % af den relative risiko) eller konservativ behandling (reduktion på 15 % af den relative risiko, p = 0,27 for interaktion).
There was a significant therapeutic benefit from the use of enoxaparin in comparison to UFH in patients undergoing percutaneous coronary angioplasty within 30 days after the random sampling (relative risk reduction of 23%) or conservative treatment (reduction of relative risk of 15%, p = 0.27 for interaction).
Der var en statistisk signifikant forbedring af PFS, TFST og TSST hos BRCA-muterede patienter (n=136).
In BRCA-mutated patients (n=136) there was a statistically significant improvement in PFS, TFST, and TSST.
Der var en statistisk signifikant forbedring i antal blodplader eller hæmoglobin i ITT-populationen til fordel for ibrutinib kontra chlorambucil.
There was a statistically significant sustained platelet or hemoglobin improvement in the ITT population in favor of ibrutinib versus chlorambucil.
Der var en statistisk signifikant forbedring i samlet overlevelse i gruppen, der fik oral topotecan plus BSC sammenlignet med gruppen, der kun fik BSC (log-rank, p=0,0104).
Oral topotecan plus BSC group had a statistically significant improvement in overall survival compared with the BSC alone group (Log-rank p=0.0104).
Der var en statistisk signifikant højere incidens af patienter med ≥ 7 % vægtstigning (fra baseline til endepunkt) sammenlignet med placebo (3,1 %) for Sycrest 2,5 mg to gange dagligt (9,5 %) og Sycrest 5 mg to gange dagligt (13,1 %).
There was a statistically significant higher incidence of patients with ≥ 7 % weight gain (from baseline to endpoint) compared to placebo (3.1 %) for Sycrest 2.5 mg twice daily (9.5 %) and Sycrest 5 mg twice daily (13.1 %).
Der var en stigning i clearance (CL) ved uge 14, der blev afhjulpet med fortsat rFVIIIFc-behandling.
There was an increase in clearance (CL) at Week 14 that resolved with continued rFVIIIFc treatment.
Der var en stigning i den gennemsnitlige cefaclor Cmax og AUC (henholdsvis 1,43 og 1,54 gange), efter gentagne doser af A771726, hvilket tyder på, at A771726 hæmmer OAT3 in vivo.
There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of A771726, suggesting that A771726 is an inhibitorof OAT 3 in vivo.
Der var en stigning i den gennemsnitlige repaglinid Cmax og AUC (henholdsvis 1,7 og 2,4 gange), efter gentagne doser af A771726, hvilket tyder på, at A771726 hæmmer CYP2C8 in vivo.
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of A771726, suggesting that A771726 is an inhibitorof CYP2C8 in vivo.
Der var en stigning i middel-cefaclor-Cmax og -AUC (henholdsvis 1,43 og 1,54 gange) efter gentagne doser teriflunomid, hvilket tyder på, at teriflunomid hæmmer OAT3 in vivo.
There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of OAT3 in vivo.
Der var en stigning i middel-repaglinid-Cmax og -AUC (henholdsvis 1,7 og 2,4 gange) efter gentagne doser teriflunomid, hvilket tyder på, at teriflunomid hæmmer CYP2C8 in vivo.
There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo.
Der var en stigning på cirka 8 %, 23 % og 34 % i hæmningen af henholdsvis delenhed LMP7, MECL1 og LMP2 ved en dosis på 56 mg/m2 sammenlignet med doser på 15 til 20 mg/m2.
There was an approximately 8%, 23% and 34% increase in the inhibition of LMP7, MECL1, and LMP2 subunits respectively at the dose of 56 mg/m2compared to those at 15 to 20 mg/m2.
Der var en svag interaktion mellem dronedaron og atorvastatin (hvilket gennemsnitligt resulterede i en 1,7-folds stigning i atorvastatin- plasmakoncentrationen).
There was a weak interaction between dronedarone and atorvastatin (which resulted in a mean 1.7-fold increase in atorvastatin exposure).
Der var en tendens til en højere tilsyneladende clearance af golimumab ved øget vægt (se pkt.
For the full list of excipients, see section 6.1.
Der var en tendens til, at de fleste bivirkninger forekom i løbet af de første 16 ugers behandling med lenalidomid.
Most adverse reactions tended to occur during the first 16 weeks of therapy with lenalidomide.
Der var en tilsvarende mindskelse af tiden i »off-tilstand« hos de patienter, der fik entacapon.
Similar reductions in time spent in the ‘off’ state were seen in patients taking entacapone.
Der var en tre gange s å høj forekomst af cerebrovaskulære hændelser hos de patienter, som blev behandlet med olanzapin, sammenlignet med patienterne, som blev behandlet med placebo (henholdsvis 1,3 % og 0,4 %).
There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3 % verses 0.4 %, respectively).
Der var en tre gange så høj forekomst af cerebrovaskulære hændelser hos de patienter, som blev behandlet med olanzapin, sammenlignet med patienterne, som blev behandlet med placebo (henholdsvis 1,3 % og 0,4 %).
There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3 % versus 0.4 %, respectively).
Der var en tydelig variation og signifikant overlap i eksponeringen mellem patienter med nedsat nyrefunktion og raske frivillige.
There was substantial variability and significant overlap in exposures between patients with renal impairment and healthy volunteers.
Der var en vedvarende effekt over tid i de fase III-studier, som varede i henholdsvis 6 måneder og 1 år.
There was a sustained effect over time in the six- months and one-year Phase III studies.
Der var en øget incidens af transitionalcellepapillom i urinblæren hos hanrotter i den gruppe, der fik den høje dosis (tilsvarende dosis for mennesker er dobbelt den maksimale dosis på 14,4 g i det kliniske studie).
There was an increased incidence of urinary bladder transitional cell papilloma in male rats of the high dose group (human equivalent dose twice the maximum clinical trial dose of 14.4 g).
Der var en øget incidens af transitionalcellepapillom i urinblæren hos hanrotter i den gruppe, der fik den høje dosis (tilsvarende dosis for mennesker er dobbelt den maksimale dosis på 14,4 g i det kliniske studier).
There was an increased incidence of urinary bladder transitional cell papilloma in male rats of the high dose group (human equivalent dose twice the maximum clinical trial dose of 14.4 g).
Der var en øget median PFS på 1,5 måneder til fordel for Cyramza plus docetaxel-armen: 4,5 måneder i Cyramza plus docetaxel- armen og 3 måneder i placebo plus docetaxel-armen.
There was an increase in median PFS of 1.5 months in favour of the Cyramza plus docetaxel arm: 4.5 months in the Cyramza plus docetaxel arm and 3 months in the placebo plus docetaxel arm.
Der var en øget risiko for tidligt dødsfald blandt patienter med stor tumorbyrde ved baseline, 16/81 (20 %) tidlige dødsfald i lenalidomidarmen og 2/28 (7 %) tidlige dødsfald i kontrolarmen.
Patients with high tumour burden at baseline are at increased risk of early death, 16/81 (20%) early deaths in the lenalidomide arm and 2/28 (7%) early deaths in the control arm.
Der var en øget tendens af intrakraniel blødning i clopidogrel + ASA behandlingen sammenlignet med placebo + ASA-gruppen (1,4 % versus 0,8 %, henholdsvis).
There was an excess of intracranial bleeding in the clopidogrel + ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively).
Der var et fald på 1,6 % hos de patienter, som supplerede deres igangværende behandling med placebo.
There was a 1.6% reduction in the patients who added placebo to their existing treatment.
Der var et gennemsnitligt fald i følsomhed for 2 gange vildtype over for tipranavir, 12 gange vildtype over for amprenavir, 55 gange vildtype over for atazanavir, 41 gange vildtype over for indinavir, 87 gange vildtype over for lopinavir, 41 gange vildtype over for nelfinavir, 195 gange vildtype over for ritonavir og 20 gange vildtype over for saquinavir.
There was an average decrease in susceptibility of 2-fold wild type (WT) for tipranavir, 12-fold WT for amprenavir, 55-fold WT for atazanavir, 41-fold WT for indinavir, 87-fold WT for lopinavir, 41- fold WT for nelfinavir, 195-fold WT for ritonavir, and 20-fold WT for saquinavir.
Der var evidens for en fordel ved telmisartan i forhold til placebo i det præspecificerede sekundære sammensatte endepunkt (kardiovaskulær død, ikke- letalt myokardieinfarkt og ikke-letal apopleksi) [0,87 (95% CI 0,76-1,00; p = 0,048)].
There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p = 0.048)].
Der var fire metaboliter tilstede i plasma ved eksponeringer (AUC) større end 10 % af moderstoffet XL184-N-oxid, XL184 amid spaltningsprodukt, XL184 monohydroxysulfat og 6-desmethylamid spaltningsprodukt sulfat.
Four metabolites were present in plasma at exposures (AUC) greater than 10% of parent: XL184-N-oxide, XL184 amide cleavage product, XL184 monohydroxy sulfate, and
Der var fire metaboliter tilstede i plasma ved eksponeringer (AUC) større end 10 % af moderstoffet: XL184-N-oxid, XL184 amid spaltningsprodukt, XL184 monohydroxysulfat og 6-desmethylamid spaltningsprodukt sulfat.
Four metabolites were present in plasma at exposures (AUC) greater than 10% of parent: XL184-N-oxide, XL184 amide cleavage product, XL184 monohydroxy sulfate, and
Der var flere bivirkninger (99,2 % vs.
There were more adverse events (99.2% vs.
Der var flere intrakranielle blødninger i clopidogrel +
There was an excess of intracranial bleeding in the clopidogrel
Der var flere intrakranielle blødninger i clopidogrel + ASA- gruppen sammenlignet med placebo + ASA-gruppen (1,4 % versus 0,8 %, henholdsvis).
There was an excess of intracranial bleeding in the clopidogrel + ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively).
Der var flere intrakranielle blødninger i clopidogrel + ASA- gruppen sammenlignet med placebo + ASA-gruppen (1,4% versus 0,8%, henholdsvis).
There was an excess of intracranial bleeding in the clopidogrel + ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively).
Der var flere intrakranielle blødninger i clopidogrel + ASA-gruppen behandlingen sammenlignet med placebo + ASA-gruppen (1,4 % versus 0,8 %, henholdsvis).
There was an excess of intracranial bleeding in the clopidogrel + ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively).
Der var flere patienter der havde ventrikulære pauser med ticagrelor (6,0 %) end med clopidogrel (3,5 %) i den akutte fase; og hhv.
More patients had ventricular pauses with ticagrelor (6.0%) than with clopidogrel (3.5%) in the acute phase; and
Der var flere patienter i vareniclin-gruppen end i placebo-gruppen, der rapporterede om selvmordstanker eller -adfærd før inklusion (anamnese) og efter endt aktiv behandling (på dag 33 til 85 efter sidste behandlingsdosis).
In the varenicline group compared to placebo, a higher proportion of subjects reported suicidal ideation or behaviour prior to enrolment (lifetime history) and after the end of active treatment period (on Days 33 to 85 after the last dose of treatments ).
Der var flere patienter  60 år, som behandledes med capecitabin plus docetaxel, som måtte stoppe behandlingen tidligt på grund af bivirkninger, sammenlignet med patienter < 60 år.
Patients 60 years of age treated with capecitabine plus docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients <60 years of age.
Der var fortsat en numerisk større andel af respondenter med en forbedring på ≥ 15 bogstaver fra baseline i BCVA hos patienter, der blev behandlet med OZURDEX, sammenlignet med sham på dag 180.
There continued to be a numerically greater proportion of responders for a ≥ 15 letter improvement from baseline in BCVA in patients treated with OZURDEX compared with sham at day 180.
Der var fortsat tegn på øget respons på behandling i op til 2,5 år hos alle grupper eksponeret for Revestive i form af reduktion i parenteralt ernæringsvolumen, opnåelse af yderligere dage uden parenteral ernæring pr. uge og opnåelse af manglende behov for parenteral støtte.
There continued to be evidence of increased response to treatment for up 2.5 years in all groups exposed to Revestive in terms of parenteral nutrition volume reduction, gaining additional days off parenteral nutrition per week, and achieving weaning of parenteral support.
Der var færre forsøgspersoner, som fik foretaget kolektomi i 5 mg/kg infliximab- gruppen (28/242 eller 11,6 % [N.S.] og 10 mg/kg infliximab-gruppen (18/242 eller 7.4 % [p = 0,011]) end i placebogruppen (36/244;14,8 %).
Fewer subjects underwent colectomy in the 5 mg/kg infliximab group (28/242 or 11.6% [N.S.]) and the 10 mg/kg infliximab group (18/242 or 7.4% [p = 0.011]) than in the placebo group (36/244; 14.8%).
Der var færre forsøgspersoner, som fik foretaget kolektomi i 5 mg/kg infliximab- gruppen (28/242 eller 11,6 % [N.S.] og 10 mg/kg infliximab-gruppen (18/242 eller 7.4 % [p=0,011]) end i placebogruppen (36/244;14,8 %).
Fewer subjects underwent colectomy in the 5 mg/kg infliximab group (28/242 or 11.6% [N.S.]) and the 10 mg/kg infliximab group (18/242 or 7.4% [p=0.011]) than in the placebo group (36/244; 14.8%).
Der var færre udbrud af Aspergillus-infektion hos patienter, der fik posaconazol forebyggende, sammenlignet med patienter i kontrolgruppen.
There were fewer breakthrough Aspergillus infections in patients receiving posaconazole prophylaxis when compared to control patients.
Der var følgende skalatrin: 1 = meget stærkt forbedret; 2 = stærkt forbedret; 3 = minimalt forbedret; 4 = ingen ændring; 5 = minimalt forværret; 6 = stærkt forværret; eller 7 = meget stærkt forværret.
1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse.
Der var generelt en tendens til, at behandlingskrævende bivirkninger aftog med tiden, måske på grund af en forbedring af den tilgrundliggende sygdomsproces.
In general, treatment-emergent adverse events tended to decrease over time, perhaps accounted for by amelioration of the underlying disease process.
Der var gennemtrængning til hjernen med akkumulering over tid ved gentagen behandling samt effektiv reduktion af koncentrationer af phospho-S6, en downstream markør for mTORC1.
There was brain penetration, with accumulation over time with repetitive treatment, and effective reduction of levels of phospho-S6, a downstream marker of mTORC1.
Der var hverken korrelation mellem antistofaktivitet og klinisk effektivitet eller mellem antistofaktivitet og sikkerhed.
There was no correlation of antibody activity with either clinical efficacy or safety.
Der var højere risiko for blødning fra slimhinder i kroppens hulrum såsom næse, tarme og skede, men udvalget fandt, at denne risiko kunne håndteres med passende foranstaltninger.
Although there was greater a risk of bleeding from the mucosa (tissues lining body cavities such as the nose, gut and vagina), the Committee considered that the risk could be managed with appropriate measures.
Der var i alt seks personer, der seponerede medicinen i denne periode, hvoraf kun et tilfælde skyldtes en bivirkning (postoperativ sårinfektion).
There were six overall discontinuations during this period, only one of which was due to an AE (the SAE of post- operative wound infection).
Der var i disse forsøg ikke nogen synlige forskelle i farmakokinetikken af topotecan hos børn, unge og yngre voksne med solide tumorer eller leukæmi, men data er for begrænsede til en definitiv konklusion.
In these studies, there were no apparent differences in the pharmacokinetics of topotecan among children, adolescents, and young adult patients with solid tumours or leukaemia, but data are too limited to draw definite conclusions.
Der var i disse forsøg ikke nogen synlige forskelle i farmakokinetikken af topotecan hos børn, unge og yngre voksne med solide tumorer ellerleukæmi, men data er for begrænsede til en definitiv konklusion.
In these studies, there were no apparent differences in the pharmacokinetics of topotecan among children, adolescents, and young adult patients with solid tumours or leukaemia, but data are too limited to draw definite conclusions.
Der var i ospemifen-gruppen en enkel forsøgsperson (0,3%), som udviklede hyperplasi af endometriet (simpel hyperplasi uden atypi) 88 dage efter den sidste dosis forsøgsmedicin.
There was a single subject (0.3%) who developed endometrial hyperplasia in the ospemifene group (simple hyperplasia without atypia) 88 days after the last dose of study drug.
Der var i samme publikation oplysning om længere varende opfølgningsdata fra 12 MDS/MPD-patienter med PDGFR- omlejring (5 patienter fra studie B2225).
The same publication reported long term follow-up data from 12 MDS/MPD patients with PDGFR gene rearrangements (5 patients from study B2225).
Der var ikke andre dabigatran relaterede anti-koagulation test, der var ændret væsentligt ved forbehandling med enoxaparin.
Other dabigatran related anti-coagulation tests were not changed significantly by the pre-treatment of enoxaparin.
Der var ikke evidens for QT/QTc- forlængelse ved en dosis på 320 mg azilsartan medoxomil.
There was no evidence of QT/QTc prolongation at a dose of 320 mg of azilsartan medoxomil.
Der var ikke forskel mellem disse patienter og yngre patienter med hensyn til sikkerhed og virkning.
No overall differences in safety or efficacy were observed between these patients and younger patients.
Der var ikke forskel på insulin glargin og standardbehandlingen med hensyn til de to primære endepunkter, delendepunkter som inkluderede disse hændelser, dødelighed uanset årsag og det sammensatte mikrovaskulære endepunkt.
There were no differences between insulin glargine and standard care for the two co- primary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.
Der var ikke klinisk forskel på de typer af bivirkninger, som patienter eksponeret for supraterapeutiske doser oplevede, og de typer af bivirkninger, som patienter, der fik administreret anbefalede doser af lacosamid, oplevede.
The types of adverse events experienced by patients exposed to supratherapeutic doses were not clinically different from those of patients administered recommended doses of lacosamide.
Der var ikke klinisk signifikante forskelle i forekomsten af hypoglykæmiske episoder i gruppen, der fik exenatid opløsning til injektion, sammenlignet med placebo-gruppen (henholdsvis 25 % og 29 %).
There were no clinically significant differences in the incidence of hypoglycaemic episodes in the immediate-release exenatide compared to the placebo group (25% and 29% respectively).
Der var ikke nogen interferens med immunresponset på japansk encefalitisvirus (JEV) eller på hepatitis A- eller rabiesvirusvacciner (se pkt.5.1).
There was no interference with the immune response to Japanese encephalitis virus (JEV) or to hepatitis A or rabies virus vaccines (see section 5.1).
Der var ikke nogen påvirkning af sikkerhed, virkning eller farmakokinetik af MabThera ved tilstedeværelse af anti-rituximab-antistoffer eller anti-rHuPH20- antistoffer.
There was no impact of the presence of anti-rituximab or anti-rHuPH20 antibodies on safety, efficacy or PK of MabThera.
Der var ikke nogen signifikant forskel på tværs af alle placebokontrollerede kliniske forsøg i brystrelaterede utilsigtede hændelser ospemifen og placebo imellem.
Across all placebo controlled clinical trials, there was no significant difference in breast related adverse events between ospemifene and placebo.
Der var ikke nogen umiddelbar påvirkning af sikkerhed og virkning ved tilstedeværelse af anti-rituximab- antistoffer eller anti-rHuPH20-antistoffer (SABRINA).
There was no apparent impact of the presence of anti-rituximab or anti-rHuPH20 antibodies on safety or efficacy (SABRINA).
Der var ikke nogen umiddelbar påvirkning af sikkerhed og virkning ved tilstedeværelse af anti-rituximab- antistoffer eller anti-rHuPH20-antistoffer.
There was no apparent impact of the presence of anti-rituximab or anti-rHuPH20 antibodies on safety or efficacy.
Der var ikke noget nyt krydsresistensmønster ved uge 96 sammenlignet med uge 48.
There were no new cross resistance patterns at week 96 compared to week 48.
Der var ikke tegn på patologisk gulsot, og 6 ud af
There was no evidence of pathologic jaundice and six of